Recommandations préanalytiques pour les analyses de protéomique clinique des fluides biologiques

Lehmann, Sylvain; Roche, Stéphane; Allory, Yves; Barthelaix, A.; Beaudeux, J.-L.; Berger, François; Betsou, Fay; Borg, Jacques; Dupuy, A; Garin, Jérôme; Quillard, M.; Lizard, Gérard; Peoc’h, Katell; Rivière, M.; Ducoroy, Patrick

doi:10.1684/abc.2009.0374

Cited by 4 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To ensure this reproducibility, a control of the initial state of samples, with standardization of sample collection, storage and preparation conditions, is required. According to Lehmann et al [ 46 ], the following pre-analytical steps have to be controlled: the sampling procedure and the type of container, the temperature and the time before transport (if transport needed), the time between sample collection and sample processing, the process itself (centrifugation, aliquoting, type of secondary container), the storage (temperature and duration) and the pre-treatment just before proteomic analysis.…”

Section: Analysis Of Blood Products Aging and Storage Lesions Biomarkmentioning

confidence: 99%

Biomarker Analysis of Stored Blood Products: Emphasis on Pre-Analytical Issues

Delobel

Rubin

Prudent

et al. 2010

IJMS

View full text Add to dashboard Cite

Millions of blood products are transfused every year; many lives are thus directly concerned by transfusion. The three main labile blood products used in transfusion are erythrocyte concentrates, platelet concentrates and fresh frozen plasma. Each of these products has to be stored according to its particular components. However, during storage, modifications or degradation of those components may occur, and are known as storage lesions. Thus, biomarker discovery of in vivo blood aging as well as in vitro labile blood products storage lesions is of high interest for the transfusion medicine community. Pre-analytical issues are of major importance in analyzing the various blood products during storage conditions as well as according to various protocols that are currently used in blood banks for their preparations. This paper will review key elements that have to be taken into account in the context of proteomic-based biomarker discovery applied to blood banking.

show abstract

Section: Analysis Of Blood Products Aging and Storage Lesions Biomarkmentioning

confidence: 99%

Biomarker Analysis of Stored Blood Products: Emphasis on Pre-Analytical Issues

Delobel

Rubin

Prudent

et al. 2010

IJMS

View full text Add to dashboard Cite

show abstract

Plasma miR-34a-5p and miR-545-3p as Early Biomarkers of Alzheimer’s Disease: Potential and Limitations

et al. 2016

View full text Add to dashboard Cite

Plasma microRNAs (miRNAs) have been proposed as potential biomarkers in Alzheimer's disease (AD). Here, we explored their use as early sensors of the preclinical phase of the disease, when brain pathology is being developed and no cognitive loss is detected. For this purpose, we analyzed a set of ten mature plasma miRNAs in symptomatic patients with AD from a cohort that also included healthy controls (HC) and patients with preclinical Alzheimer's disease (PAD) (cohort 1). Plasmas from subjects with Parkinson's disease (PD) were used to control for disease specificity. We found that miR-15b-5p, miR-34a-5p, miR-142-3p, and miR-545-3p levels significantly distinguished AD from PD and HC subjects. We next examined the expression of these four miRNAs in plasma from subjects with PAD. Among these, miR-34a-5p and miR-545-3p presented good diagnostic accuracy to distinguish both AD and PAD from HC subjects, according to the receiver operating characteristic (ROC) curve analysis. Both miRNAs also demonstrated a significant positive correlation with Aβ1-42 levels in cerebrospinal fluid (CSF). Taking into account the clinical potential of these findings, we decided to validate the diagnostic accuracy of miR-34a-5p and miR-545-3p in plasma samples from an independent cohort (cohort 2), in which we did not observe the alterations described by us and others in AD and PAD samples. Although miR-34a-5p and miR-545-3p might be promising early biomarker candidates for AD, our study highlights possible sources of variability in miRNA analysis across hospitals, which currently prevents their use as reliable clinical tools.

show abstract